| Literature DB >> 33603487 |
Xin Zhou1, Shou-Gen Cao1, Xiao-Jie Tan1, Xiao-Dong Liu1, Ze-Qun Li1, Ling-Xin Kong2, Yu-Long Tian1, Dan Liu1, Shuai Shen1, Yu-Qi Sun1, Hai-Tao Jiang1, Yan-Bing Zhou1.
Abstract
PURPOSE: Transcutaneous electrical acupoint stimulation (TEAS) is an innovative choice for postoperative pain management. However, the safety and effectiveness of this traditional Chinese medicine (TCM) therapy for patients who underwent gastrectomy is largely unknown. So, the purpose of this study is to evaluate the safety and effectiveness of TEAS for patients who underwent gastrectomy. PATIENTS AND METHODS: We recruited 96 patients with gastric cancer from May 2019 to November 2019; 82 patients were enrolled, and 81 patients completed. Patients were randomly assigned to TEAS group (TG) received TEAS on postoperative day (POD) 1-3 or control group (CG) at a 1:1 ratio. The primary outcomes were pain score and consumption of analgesics. The secondary were the time of first postoperative flatus and defecation, frequency of postoperative nausea, vomiting, distention, diarrhea, comfort of semi-fluid diet, Clavien-Dindo grade (C-D grade) and length of postoperative day. We performed hematological analysis to explore the possible mechanisms.Entities:
Keywords: acupuncture therapy; enhanced recovery after surgery; gastrointestinal function; pain management; stomach neoplasms
Year: 2021 PMID: 33603487 PMCID: PMC7886100 DOI: 10.2147/CMAR.S292325
Source DB: PubMed Journal: Cancer Manag Res ISSN: 1179-1322 Impact factor: 3.989
Figure 1Participant flow diagram.
Clinicopathological Characteristics of Patients (n=81)
| TG | CG | |
|---|---|---|
| (n=41) | (n=40) | |
| Age (years) | 0.304 a | |
| Mean±SD | 58.71±9.274 | 60.83±9.137 |
| Gender | 0.689 b | |
| Male, n (%) | 27 (65.9) | 28 (70.0) |
| Female, n (%) | 14 (34.1) | 12 (30.0) |
| BMI (kg/m2) | 0.988 a | |
| Mean±SD | 23.93±2.823 | 23.93±2.696 |
| ASA grade, n (%) | 0.310 c | |
| 1 | 0 (0.00) | 0 (0.00) |
| 2 | 35 (85.4) | 37 (92.5) |
| 3 | 6 (14.6) | 3 (7.50) |
| CCI | 0.342 c | |
| Mean±SD | 3.95±1.26 | 4.20±1.20 |
| NRS 2002 score | 0.359 c | |
| Mean±SD | 1.65±1.85 | 2.05±1.80 |
| Smoker, n (%) | 0.585 b | |
| 24 (58.5) | 21 (52.5) | |
| Drinker, n (%) | 0.586 b | |
| 15 (36.6) | 17 (42.5) | |
| Abdominal pain, n (%) | 0.882 b | |
| 26 (63.4) | 26 (65.0) | |
| Abdominal distention, n (%) | 0.094 b | |
| 13 (31.7) | 20 (50.0) | |
| Diarrhea, n (%) | 0.980 b | |
| 2 (4.90) | 2 (5.00) | |
| Constipation, n (%) | 0.667 b | |
| 3 (7.30) | 4 (10.0) | |
| Nausea, n (%) | 0.503 b | |
| 13 (31.7) | 10 (25.0) | |
| Vomiting, n (%) | 0.753 b | |
| 5 (12.2) | 4 (10.0) | |
| Appetite loss, n (%) | 0.558 b | |
| 18 (43.9) | 15 (37.5) | |
| cTNM stage, n (%) | 0.807 c | |
| I | 18 (43.9) | 16 (40.0) |
| II | 7 (17.1) | 8 (20.0) |
| III | 16 (39.0) | 16 (40.0) |
Notes: at-test; bChi-squared test (Χ2); cWilcoxon rank sum test.
Abbreviations: BMI, body mass index; ASA, American Society of Anesthesiologists; CCI, Charlson Comorbidity Index; NRS, nutrition risk screening.
Surgical Outcomes (n=81)
| TG | CG | |
|---|---|---|
| (n=41) | (n=40) | |
| Time (min) | 0.292 a | |
| Mean±SD | 228.97±71.27 | 207.90±48.84 |
| Blood loss (mL) | 0.188 c | |
| Mean±SD | 61.71±55.40 | 93.25±156.1 |
| Surgical approach, n (%) | 0.439 b | |
| Laparoscopy | 27 (65.9) | 23 (57.5) |
| Robot | 14 (34.1) | 17 (42.5) |
| Gastrectomy, n (%) | 0.105 b | |
| Distal | 30 (73.2) | 35 (87.5) |
| Total | 11 (26.8) | 5 (12.5) |
| Type of reconstruction, n (%) | 0.238 b | |
| Roux-en-Y | 36 (87.8) | 30 (75.0) |
| Billroth-II | 5 (12.2) | 10 (25.0) |
Notes: at-test; bChi-squared test (Χ2); cWilcoxon rank sum test.
Primary Outcomes (n=81)
| TG | CG | |||
|---|---|---|---|---|
| (n=41) | (n=40) | |||
| PAIN SCORE | ||||
| Average of POD 1–5 | ||||
| Mean±SD | 2.55±0.21 | 3.10±0.42 | ||
| POD 0 | ||||
| Mean±SD | 3.58±0.60 | 3.83±0.84 | ||
| POD 1 | ||||
| Median (Quartile) | 3.00 (0.42) | 3.33 (0.67) | ||
| POD 2 | ||||
| Median (Quartile) | 2.58 (0.29) | 3.17 (0.58) | ||
| POD 3 | ||||
| Median (Quartile) | 2.25 (0.33) | 3.08 (0.75) | ||
| POD 4 | ||||
| Median (Quartile) | 2.00 (0.17) | 2.83 (0.58) | ||
| POD 5 | ||||
| Median (Quartile) | 1.75 (0.21) | 2.29 (0.73) | ||
| Group | Wald Chi-Square | 78.296 | <0.001 c | |
| Time | Wald Chi-Square | 419.405 | <0.001 c | |
| Group*Time | Wald Chi-Square | 9.155 | 0.057 c | |
| ANALGESICS DATA | ||||
| Dose of Flurbiprofen axetil, n (%) | 0.117 b | |||
| Mean±SD | 120.0±12.82 | 145.9±13.22 | ||
| Use rate of opioids, n (%) | 0.004 a | |||
| 18 (43.9) | 30 (75.0) | |||
| Equivalent dose of morphine (mg)• | 0.182 b | |||
| Mean±SD | 8.935±3.660 | 12.83±8.097 | ||
Notes: aChi-squared test (Χ2); bWilcoxon rank sum test; cGeneralized estimating equation; •We used an equivalent dose of morphine, pethidine: pentazocine: dezocine: morphine=100mg: 45mg: 10mg: 10mg.
Abbreviation: POD, postoperative day.
Figure 2(A) Pain Score. Comparing the pain scores of the two groups, no significant difference was found on POD 0 (P=0.105). Scores of TG were significantly lower on POD 1–5 (P<0.001). (B) Consumption of analgesics. The use rate of opioid was significantly lower in TG (P=0.004). As for the consumption of NSAIDs and the equivalent doses of morphine, no significant difference was found (P>0.05).
Secondary Outcomes (n=81)
| TG | CG | |
|---|---|---|
| (n=41) | (n=40) | |
| Time of first flatus (h) | <0.001 b | |
| Mean±SD | 55.63±16.74 | 72.60±20.92 |
| Time of first defecation (h) | <0.001 b | |
| Mean±SD | 72.20±16.24 | 95.78±17.75 |
| Nausea, n (%) | 0.441 a | |
| 16 (39.0) | 19 (47.5) | |
| Vomiting, n (%) | 1.00 a | |
| 0 (0.00) | 0 (0.00) | |
| Distension, n (%) | 0.051 a | |
| 10 (24.4) | 18 (45.0) | |
| Diarrhea, n (%) | 0.054 a | |
| 3 (7.30) | 9 (22.5) | |
| Fever, n (%) | 0.753 a | |
| 36 (87.8) | 36 (90.0) | |
| Frequency of nausea | 0.029 b | |
| Mean±SD | 1.88±1.09 | 2.58±0.77 |
| Frequency of vomiting | 1.00 b | |
| Mean±SD | 0 | 0 |
| Frequency of distension | 0.213 b | |
| Mean±SD | 2.60±1.27 | 3.50±2.01 |
| Frequency of diarrhea | 0.727 b | |
| Mean±SD | 2.00±1.00 | 2.33±1.12 |
| Frequency of fever | 0.419 b | |
| Mean±SD | 6.35±4.03 | 7.61±6.13 |
| Comfort of semi-fluid | <0.001 b | |
| Mean±SD | 7.63±0.63 | 6.93±0.69 |
| C-D grade, n (%)• | 0.292 a | |
| Grade 0 | 1 (2.40) | 2 (5.00) |
| Grade 1 | 39 (95.1) | 34 (85.0) |
| Grade 2 | 1 (2.40) | 4 (10.0) |
| Length of postoperative stay (d) | 0.478 b | |
| Mean±SD | 6.12±1.29 | 6.45±1.68 |
Notes: aChi-squared test (Χ2); bWilcoxon rank sum test; •The C-D grade was used for postoperative complications grade; Patients with a grade>2 met the withdrawal criteria and were not included in the analysis.
Abbreviation: C-D grade, Clavien-Dindo grade.
Hematological Results (TG=41; CG=40)
| POD 1 | POD 3 | POD5 | Analysis Wald Chi-Square (Group) | ||
|---|---|---|---|---|---|
| Median (Quartile) | Median (Quartile) | Median (Quartile) | |||
| WBC (109/L) | TG | 10.64 (3.735) | 7.320 (2.625) | 6.480 (1.590) | 0.571 |
| CG | 12.15 (4.668) | 7.190 (3.678) | 6.425 (2.850) | 0.450 d | |
| NEC% | TG | 83.10 (9.650) | 73.90 (10.45) | 69.80 (5.400) | 0.070 |
| CG | 83.95 (12.83) | 75.25 (9.275) | 67.60 (9.675) | 0.791 d | |
| CRP (mg/L) | TG | 14.74 (12.86) | 61.71 (34.26) | 27.33 (23.71) | 2.909 |
| CG | 21.00 (13.57) | 67.57 (37.69) | 31.54 (24.40) | 0.088 d | |
| PCT (ng/mL) | TG | 0.103 (0.111) | 0.255 (0.180) | 0.092 (0.052) | 2.853 |
| CG | 0.112 (0.104) | 0.275 (0.258) | 0.136 (0.117) | 0.091 d | |
| β-End (pg/mL) | TG | 49.16 (8.08) | 73.92 (6.38) | 68.20 (2.450) | 467.661 |
| CG | 50.53 (6.11) | 59.48 (4.46) | 53.31 (4.070) | <0.001 d | |
| 5-HT (pg/mL) | TG | 2137.82 (353.19) | 1607.72 (272.86) 1852.97 (295.24) | 1330.91 (459.38) | 28.013 |
| CG | 2049.37 (176.22) | 1556.23 (359.15) | <0.001 d | ||
| IL-2 (ng/mL) | TG | 4.740 (1.210) | 7.810 (2.640) | 9.590 (3.190) | 52.534 |
| CG | 4.535 (1.420) | 6.295 (0.800) | 7.665 (1.050) | <0.001 d | |
| IL-6 (pg/mL) | TG | 45.41 (7.690) | 39.17 (12.57) | 31.83 (4.270) | 33.888 |
| CG | 46.08 (7.800) | 42.46 (3.520) | 35.60 (2.260) | <0.001 d | |
| TNF-α (pg/mL) | TG | 48.53 (5.700) | 36.89 (10.99) | 27.53 (5.700) | 20.734 |
| CG | 48.55 (6.770) | 41.38 (6.690) | 31.12 (4.620) | <0.001 d | |
| MTL (pg/mL) | TG | 392.44 (127.48) | 522.78 (127.71) | 647.68 (157.06) | 36.611 |
| CG | 397.45 (133.54) | 486.90 (68.840) | 556.70 (93.69) | <0.001 d | |
Note: dGeneralized estimating equation.
Abbreviations: WBC, white blood cell count; NEC%, percentage of neutrophils; CRP, C-reactive protein; PCT, procalcitonin; β-End, β-endorphin; 5-HT, 5-hydroxytryptamine; IL-2, interleukin-2; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α; MTL, motilin.